Titan Pharmaceuticals, Inc. (TTNP) Director James R. Mcnab Buys 200,000 Shares of Stock

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Director James R. Mcnab bought 200,000 shares of the firm’s stock in a transaction dated Friday, September 21st. The shares were purchased at an average price of $0.25 per share, with a total value of $50,000.00. Following the acquisition, the director now directly owns 300,000 shares in the company, valued at approximately $75,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

NASDAQ TTNP opened at $0.22 on Wednesday. The company has a market capitalization of $4.59 million, a price-to-earnings ratio of -0.31 and a beta of 1.16. Titan Pharmaceuticals, Inc. has a fifty-two week low of $0.22 and a fifty-two week high of $2.85. The company has a debt-to-equity ratio of -2.70, a current ratio of 1.76 and a quick ratio of 1.21.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its quarterly earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.09. The firm had revenue of $2.67 million during the quarter, compared to analysts’ expectations of $0.07 million. Titan Pharmaceuticals had a negative return on equity of 1,659.34% and a negative net margin of 295.69%. sell-side analysts forecast that Titan Pharmaceuticals, Inc. will post -0.41 earnings per share for the current fiscal year.

Separately, ValuEngine upgraded Titan Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

Recommended Story: How Do I Invest in Dividend Stocks

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply